
- BioPharm International-05-01-2019
- Volume 32
- Issue 5
New Kit Identifies Endonuclease Impurities
The EndonucleaseGTP ELISA Kit from Cygnus Technologies detects and quantitates residual endonuclease impurities in recombinant vaccines and viral vectors used for gene therapy.
The EndonucleaseGTP ELISA Kit from Cygnus Technologies detects and quantitates residual endonuclease impurities in recombinant vaccines and viral vectors used for gene therapy. With a detection limit of ~0.06 ng/mL, the kit is three times more sensitive than the only other commercially available assay for detection and quantitation of these endonuclease impurities, according to the company. The kit also contains all the necessary, ready-to-use reagents for 96 analyses in microplate format, including a set of calibrated endonuclease standards. The assay can be easily integrated into desired workflow points-from process development to quality control to lot release testing.
Articles in this issue
over 6 years ago
Optimizing Diaphragm Valves to Improve Bioprocess Reliabilityover 6 years ago
What’s New in Upstream Technologiesover 6 years ago
FDA Faces Challenges After Gottliebover 6 years ago
Bioprocessing Facilities and FDA Inspection Problemsover 6 years ago
The Auditor Vs. Inspector Issueover 6 years ago
Multichannel Pipettes for 384-Well Platesover 6 years ago
Challenges with Successful Commercialization of Biosimilarsover 6 years ago
Single-Use for Downstream Chromatography: Benefit or Hindrance?over 6 years ago
Playing the Waiting Game with GMP Guideline RevisionsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.